Melanoma tumor vaccine: Five‐year follow‐up

J. Michael C. McGee, Glenn H. Lytle, Karen F. Malnar, Joseph A. Price, Loren J. Humphrey

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

For many years, various melanoma vaccines have been employed. This is a unique melanoma vaccine in that it is a subcellular tumor homogenate and no adjuvants have been added. This vaccine has been given to 129 stage I and 61 stage II melanoma patients. All were followed at least 5 years and had 87.5% and 63.9% 5‐year survival rates, respectively. Sixty‐four stage I males and 65 stage I females had 84% and 90% 5‐year survival rates, respectively. We saw no difference between those with or without lymph node dissection. Thirty‐six stage II males and 25 stage II females had 66.7% and 60% 5‐year survival rates, respectively. Of stage II patients, 23 had only one positive node, 22 had two to four positive nodes, and 9 had five or more positive nodes with 69%, 63%, and 55% 5‐year survival rates, respectively. Large published series were used as historical controls [6,27,28], and significant differences were noted when compared to our stage II patients (P = 0.001)—those with two to four positive nodes (P = 0.03), and those with five or more positive nodes (P = 0.04). We conclude that there is a significant increase in survival for these stage II patients, at high risk of recurrence, receiving a tumor homogenate vaccine. This vaccine warrants further analysis, development, and use in a phase III randomized clinical trial.

Original languageEnglish
Pages (from-to)233-238
Number of pages6
JournalJournal of Surgical Oncology
Volume47
Issue number4
DOIs
StatePublished - Aug 1991

Fingerprint

Cancer Vaccines
Melanoma
Vaccines
Survival Rate
Phase III Clinical Trials
Lymph Node Excision
Randomized Controlled Trials
Recurrence
Survival
Neoplasms

Keywords

  • 5‐year survival
  • immunotherapy
  • tumor homogenate

Cite this

McGee, J. M. C., Lytle, G. H., Malnar, K. F., Price, J. A., & Humphrey, L. J. (1991). Melanoma tumor vaccine: Five‐year follow‐up. Journal of Surgical Oncology, 47(4), 233-238. https://doi.org/10.1002/jso.2930470407
McGee, J. Michael C. ; Lytle, Glenn H. ; Malnar, Karen F. ; Price, Joseph A. ; Humphrey, Loren J. / Melanoma tumor vaccine : Five‐year follow‐up. In: Journal of Surgical Oncology. 1991 ; Vol. 47, No. 4. pp. 233-238.
@article{e9ae86ae8fc64d5bacf85d7a0a093187,
title = "Melanoma tumor vaccine: Five‐year follow‐up",
abstract = "For many years, various melanoma vaccines have been employed. This is a unique melanoma vaccine in that it is a subcellular tumor homogenate and no adjuvants have been added. This vaccine has been given to 129 stage I and 61 stage II melanoma patients. All were followed at least 5 years and had 87.5{\%} and 63.9{\%} 5‐year survival rates, respectively. Sixty‐four stage I males and 65 stage I females had 84{\%} and 90{\%} 5‐year survival rates, respectively. We saw no difference between those with or without lymph node dissection. Thirty‐six stage II males and 25 stage II females had 66.7{\%} and 60{\%} 5‐year survival rates, respectively. Of stage II patients, 23 had only one positive node, 22 had two to four positive nodes, and 9 had five or more positive nodes with 69{\%}, 63{\%}, and 55{\%} 5‐year survival rates, respectively. Large published series were used as historical controls [6,27,28], and significant differences were noted when compared to our stage II patients (P = 0.001)—those with two to four positive nodes (P = 0.03), and those with five or more positive nodes (P = 0.04). We conclude that there is a significant increase in survival for these stage II patients, at high risk of recurrence, receiving a tumor homogenate vaccine. This vaccine warrants further analysis, development, and use in a phase III randomized clinical trial.",
keywords = "5‐year survival, immunotherapy, tumor homogenate",
author = "McGee, {J. Michael C.} and Lytle, {Glenn H.} and Malnar, {Karen F.} and Price, {Joseph A.} and Humphrey, {Loren J.}",
year = "1991",
month = "8",
doi = "10.1002/jso.2930470407",
language = "English",
volume = "47",
pages = "233--238",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "4",

}

McGee, JMC, Lytle, GH, Malnar, KF, Price, JA & Humphrey, LJ 1991, 'Melanoma tumor vaccine: Five‐year follow‐up', Journal of Surgical Oncology, vol. 47, no. 4, pp. 233-238. https://doi.org/10.1002/jso.2930470407

Melanoma tumor vaccine : Five‐year follow‐up. / McGee, J. Michael C.; Lytle, Glenn H.; Malnar, Karen F.; Price, Joseph A.; Humphrey, Loren J.

In: Journal of Surgical Oncology, Vol. 47, No. 4, 08.1991, p. 233-238.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Melanoma tumor vaccine

T2 - Five‐year follow‐up

AU - McGee, J. Michael C.

AU - Lytle, Glenn H.

AU - Malnar, Karen F.

AU - Price, Joseph A.

AU - Humphrey, Loren J.

PY - 1991/8

Y1 - 1991/8

N2 - For many years, various melanoma vaccines have been employed. This is a unique melanoma vaccine in that it is a subcellular tumor homogenate and no adjuvants have been added. This vaccine has been given to 129 stage I and 61 stage II melanoma patients. All were followed at least 5 years and had 87.5% and 63.9% 5‐year survival rates, respectively. Sixty‐four stage I males and 65 stage I females had 84% and 90% 5‐year survival rates, respectively. We saw no difference between those with or without lymph node dissection. Thirty‐six stage II males and 25 stage II females had 66.7% and 60% 5‐year survival rates, respectively. Of stage II patients, 23 had only one positive node, 22 had two to four positive nodes, and 9 had five or more positive nodes with 69%, 63%, and 55% 5‐year survival rates, respectively. Large published series were used as historical controls [6,27,28], and significant differences were noted when compared to our stage II patients (P = 0.001)—those with two to four positive nodes (P = 0.03), and those with five or more positive nodes (P = 0.04). We conclude that there is a significant increase in survival for these stage II patients, at high risk of recurrence, receiving a tumor homogenate vaccine. This vaccine warrants further analysis, development, and use in a phase III randomized clinical trial.

AB - For many years, various melanoma vaccines have been employed. This is a unique melanoma vaccine in that it is a subcellular tumor homogenate and no adjuvants have been added. This vaccine has been given to 129 stage I and 61 stage II melanoma patients. All were followed at least 5 years and had 87.5% and 63.9% 5‐year survival rates, respectively. Sixty‐four stage I males and 65 stage I females had 84% and 90% 5‐year survival rates, respectively. We saw no difference between those with or without lymph node dissection. Thirty‐six stage II males and 25 stage II females had 66.7% and 60% 5‐year survival rates, respectively. Of stage II patients, 23 had only one positive node, 22 had two to four positive nodes, and 9 had five or more positive nodes with 69%, 63%, and 55% 5‐year survival rates, respectively. Large published series were used as historical controls [6,27,28], and significant differences were noted when compared to our stage II patients (P = 0.001)—those with two to four positive nodes (P = 0.03), and those with five or more positive nodes (P = 0.04). We conclude that there is a significant increase in survival for these stage II patients, at high risk of recurrence, receiving a tumor homogenate vaccine. This vaccine warrants further analysis, development, and use in a phase III randomized clinical trial.

KW - 5‐year survival

KW - immunotherapy

KW - tumor homogenate

UR - http://www.scopus.com/inward/record.url?scp=0025867186&partnerID=8YFLogxK

U2 - 10.1002/jso.2930470407

DO - 10.1002/jso.2930470407

M3 - Article

C2 - 1861495

AN - SCOPUS:0025867186

VL - 47

SP - 233

EP - 238

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -